Kazia Therapeutics
Tracked across 2 events · 29 articles · First seen Jul 20, 2026 · Last active Sep 01, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Kazia is the issuer and primary beneficiary of the offering, raising $40 million upfront with potential for $80 million more from warrant exercises. The capital will fund clinical development of paxalisib, enhancing its financial position and supporting its pipeline.
Jul 20, 2026 · 22 articles
Tech
Impact: Kazia is the developer of paxalisib and the primary beneficiary of the positive preclinical data, which supports its advancement into a Phase 2 trial and strengthens its pipeline.
Jul 20, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Kazia Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard